Cancer Communications

Table 5 Univariate analysis of prognostic factors for patients with locoregionally advanced NPC

From: Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

Variate	5-year survival rate (%)
Variate	OS	P	LRRFS	P	DMFS	P	DFS	P
Gender		0.173		0.587		0.077		0.224
Male	75.8		87.1		75.3		65.9
Female	88.0		83.3		85.8		74.0
Age (years)		0.002		0.489		0.025		0.007
<50	82.8		87.0		81.5		73.1
≥50	68.6		84.6		68.4		55.6
WHO histology		0.362		0.564		0.526		0.549
Type II	87.1		90.3		83.3		74.5
Type III	77.5		85.8		76.9		66.9
T stage		0.213		0.070		0.773		0.299
T1–2	84.4		96.4		81.3		78.1
T3–4	77.4		84.6		76.9		66.0
N stage		0.934		0.475		0.414		0.994
N0–1	80.8		85.2		79.4		67.2
N2–3	75.1		87.8		74.9		68.2
Overall stage		<0.001		0.518		0.001		0.004
III	85.6		87.7		84.9		74.7
IV	66.5		83.5		65.3		56.2
Treatment		0.599		0.515		0.456		0.517
NAC + IMRT	78.0		87.9		79.0		69.8
CCRT + AC	78.7		84.8		76.2		65.6

Back to article page

ISSN: 2523-3548

Contact us

General enquiries: info@biomedcentral.com